Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Q1 2023 Earnings Conference Call May 8, 2023 8:00 AM ET

Company Participants

Robert Doody - Head of Investor Relations

Douglas Manion - Chief Executive Officer

Gail Cawkwell - Senior Key Executive

Joseph Monahan - Chief Scientific Officer

Kevin Balthaser - Chief Financial Officer

Conference Call Participants

Louise Chen - Cantor Fitzgerald

Corinne Jenkins - Goldman Sachs

Thomas Smith - SVB Securities

Alexander Thompson - Stifel

Roger Song - Jefferies

Dipesh Patel - Wainwright

Julian Harrison - BTIG

Lachlan Hanbury-Brown - William Blair & Company

Operator

Good day and thank you for standing by. Welcome to Aclaris Therapeutics First Quarter 2023 Conference Call. At this time, all participants are in a listen-only mode. [Operator Instructions] Please be advised that today's conference is being recorded.

I would now like to hand the conference over to your speaker today, Robert Doody, Head of Investor Relations. Please go ahead.

Robert Doody

Thank you. I am Robert Doody, Head of Investor Relations for Aclaris. Please note that earlier today, we issued a press release highlighting our first quarter 2023 financial results and other business matters.

For those of you who have not yet seen it, you will find the press release posted under the press releases page of the Investors section of our website www.aclaristx.com. In addition, we will be referring to a slide deck entitled Q1 2023 investor conference call, which can be found on the Investor page of our corporate website and furnished as an exhibit to our Form 8-K that we filed with the SEC earlier this morning.

Joining me today for the call are Doug Manion, our Chief Executive Officer; Gail Cawkwell, our Chief Medical Officer; Joe Monahan, our Chief Scientific Officer; and Kevin Balthaser,, our Chief Financial Officer.

Before we begin our prepared remarks, I would like to remind you that various statements we make during this call about the company's future results of operations and financial position, business strategy and plans and objectives for Aclaris' future operations, are considered forward-looking statements within the meaning of federal securities laws.

Our forward-looking statements are based upon current expectations that involve risks, changes in circumstances, assumptions and uncertainties that could cause actual results to differ materially from those reflected in such statements.

These risks are described in the Risk Factors section of Aclaris' Form 10-K for the year ended December 31st, 2022 and other filings Aclaris makes with the SEC from time to time. These documents are available under the SEC filings page of the Investors section of the Aclaris' website www.aclaristx.com.